Bioequivalence and comparison of pharmacokinetic properties of 4-mg tablet formulations of rosiglitazone hydrochloride and rosiglitazone maleate: A single-dose, randomized, open-label, two-period crossover study in healthy adult male Chinese volunteers

Clinical Therapeutics

Volumn 30, Issue 12, 2008, Pages 2272-2279

  Yu, Jia ^a   Ma, Ke ^a,b   Qi, Jinwen ^a   Jin, Ge ^a   Wang, Yan ^a   Fang, Shungan ^a   Li, Gonghua ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

bioequivalence; Chinese; HPLC; pharmacokinetics; rosiglitazone hydrochloride; rosiglitazone maleate

Indexed keywords

ROSIGLITAZONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BIOEQUIVALENCE; BLOOD CHEMISTRY; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG TOLERABILITY; HUMAN; KIDNEY FUNCTION; LABORATORY TEST; LIVER FUNCTION; MALE; NORMAL HUMAN; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TABLET FORMULATION; URINALYSIS;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FLUORESCENCE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; TABLETS; THERAPEUTIC EQUIVALENCY; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 58249139465     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.12.011     Document Type: Article

References (20)

1. Young P.W., Buckle D.R., Cantello B.C., et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferatoractivated receptor gamma. J Pharmacol Exp Ther 284 (1998) 751-759
2. Cheng A.Y., and Fantus I.G. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 172 (2005) 213-226
3. Baldwin S.J., Clarke S.E., and Chenery R.J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48 (1999) 424-432
4. Hanefeld M., Patwardhan R., Jones N.P., and for the Rosiglitazone Clinical Trials Study Group. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. Nutr Metab Cardiovasc Dis 17 (2007) 13-23
5. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. [published correction appears in N Engl J Med. 2007;357:100]. N Engl J Med 356 (2007) 2457-2471
6. Cox P.J., Ryan D.A., Hollis F.J., et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedi one insulin sensitizer, in humans. Drug Metab Dispos 28 (2000) 772-780
7. Phillips L.S., Grunberger G., Miller E., et al., for the Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. [published correction appears in Diabetes Care. 2001;24:973]. Diabetes Care 24 (2001) 308-315
8. Miller A.K., DiCicco R.A., and Freed M.I. The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. Clin Ther 24 (2002) 1062-1071
9. State Food and Drug Administration. Provisions for Drug Registration [SDA Web site]. http://www.sda.gov.cn/WS01/CL0053/24529.html. Accessed July 10, 2007.
10. Beijing Dezhong Wanquan Medicines Technological Development Co. Ltd., Beijing, People's Republic of China.
11. Avandia (rosiglitazone maleate) [product information] [GlaxoSmithKline Web site]. http://www.fda.gov/medwatch/SAFETY/2004/may_PI/Avandia_PI.pdf Accessed November 16, 2008.
12. World Medical Association. WMA Declaration of Helsinki. Ethical principles for medical research involving human subjects. http://www.wma.net/e/policy/b3.htm Accessed August 16, 2006.
13. State Food and Drug Administration. Good Clinical Practice Guideline. http://www.sda.gov.cn/WS01/CL0053/24473.html Accessed August 6, 2003.
14. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations [CDER Web site]. http://www.fda.gov/cder/guidance/4964dft.htm Accessed November 21, 2008.
15. US Food and Drug Administration. In vivo bioequivalence guidances. Pharmacopeial Forum 19 (1993) 6501-6508
16. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15 (1987) 657-680
17. Gao X., Yao G., Guo N., et al. A simple and rapid high performance liquid chromatography method to determine levofloxacin in human plasma and its use in a bioequivalence study. Drug Discov Ther 1 (2007) 136-140
18. Power and sample size determination. In: Chow S.-C., and Liu J.-P. (Eds). Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed (2000), Marcel Dekker, New York, NY 125-160
19. Yusuf A., Al-Gaai E., and Hammami M.M. Bioequivalence evaluation of two rosiglitazone tablet formulations. Arzneimittelforschung 56 (2006) 740-743
20. Chu K.M., Hu O.Y., Pao L.H., and Hsiong C.H. Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparidosage sons with Caucasian, Japanese, Korean, and mainland Chinese subjects. J Pharm Pharm Sci 10 (2007) 411-419